Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation

References

• Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. 2000. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 28(8):966–972.
   PubMed Web of Science ®Google Scholar
• Antherieu S, Chesne C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, et al. 2010. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos. 38(3):516–525. doi:10.1124/dmd.109.030197.
   PubMed Web of Science ®Google Scholar
• Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Jr. 2003. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5 + 1 cocktail". Clin Pharmacol Ther. 74(5):437–447. doi:10.1016/S0009-9236(03)00229-7.
   PubMed Web of Science ®Google Scholar
• Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P, Domergue J, Joyeux H, Fourtanier G, et al. 1994. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther. 269(1):384–392.
   PubMed Web of Science ®Google Scholar
• Daujat M, Peryt B, Lesca P, Fourtanier G, Domergue J, Maurel P. 1992. Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem Biophys Res Commun. 188(2):820–825. doi:10.1016/0006-291x(92)91130-i.
   PubMed Web of Science ®Google Scholar
• Ferguson MJ, Randles ML, de Freitas DG. 2017. A suspected case of autoinduction of voriconazole metabolism in a patient with cerebral aspergillosis. Drug Healthc Patient Saf. 9:89–91. doi:10.2147/DHPS.S140213.
   PubMed Web of Science ®Google Scholar
• Graham RA, Downey A, Mudra D, Krueger L, Carroll K, Chengelis C, Madan A, Parkinson A. 2002. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos. 30(11):1206–1213. doi:10.1124/dmd.30.11.1206.
   PubMed Web of Science ®Google Scholar
• Graham RA, Tyler LO, Krol WL, Silver IS, Webster LO, Clark P, Chen L, Banks T, LeCluyse EL. 2006. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes. J Biochem Mol Toxicol. 20(2):69–78. doi:10.1002/jbt.20118.
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. 2008. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 48(6):662–670. doi:10.1177/0091270007312153.
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. 2010. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 69(3):222–230. doi:10.1111/j.1365-2125.2009.03578.x.
   PubMed Web of Science ®Google Scholar
• Lu C, Li AP. 2001. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact. 134(3):271–281. doi:10.1016/s0009-2797(01)00162-4.
   PubMed Web of Science ®Google Scholar
• Murayama N, Kazuki Y, Satoh D, Arata K, Harada T, Shibata N, Guengerich FP, Yamazaki H. 2017. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 42(3):343–348. eng. doi:10.2131/jts.42.343.
   PubMed Web of Science ®Google Scholar
• Murayama N, Usui T, Slawny N, Chesne C, Yamazaki H. 2015. Human HepaRG cells can be cultured in hanging-drop plates for cytochrome P450 induction and function assays. Drug Metab Lett. 9(1):3–7. eng. doi:10.2174/1872312809666150119104806.
   PubMedGoogle Scholar
• Murayama N, Yamazaki H. 2018. Cytochrome P450-dependent drug oxidation activities in commercially available hepatocytes derived from human induced pluripotent stem cells cultured for 3 weeks [3]. J Toxicol Sci. 43(4):241–245. doi:10.2131/jts.43.241.
   PubMed Web of Science ®Google Scholar
• Nishibe Y, Hirata M. 1993. Effect of phenobarbital and other model inducers on cytochrome P450 isoenzymes in primary culture of dog hepatocytes. Xenobiotica. 23(6):681–692. doi:10.3109/00498259309059405.
   PubMed Web of Science ®Google Scholar
• Nishibe Y, Wakabayashi M, Harauchi T, Ohno K. 1998. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica. 28(6):549–557. doi:10.1080/004982598239308.
   PubMed Web of Science ®Google Scholar
• Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. 2015. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 43(11):1823–1837. doi:10.1124/dmd.115.065920.
   PubMed Web of Science ®Google Scholar
• Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. 1999. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol. 18(2):95–105. doi:10.1177/096032719901800206.
   PubMed Web of Science ®Google Scholar
• Turpault S, Brian W, Van HR, Santoni A, Poitiers F, Donazzolo Y, Boulenc X. 2009. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 68(6):928–935. doi:10.1111/j.1365-2125.2009.03548.x.
   PubMed Web of Science ®Google Scholar
• Uehara S, Higuchi Y, Yoneda N, Ito R, Takahashi T, Murayama N, Yamazaki H, Murai K, Hikita H, Takehara T, et al. 2023. HepaSH cells: experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes. Biochem Biophys Res Commun. 663:132–141. doi:10.1016/j.bbrc.2023.04.054.
   PubMed Web of Science ®Google Scholar
• Uehara S, Kawano M, Murayama N, Uno Y, Utoh M, Inoue T, Sasaki E, Yamazaki H. 2016. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. Biochem Pharmacol. 120:56–62. ENG. doi:10.1016/j.bcp.2016.09.010.
   PubMed Web of Science ®Google Scholar
• Uno Y, Jikuya S, Noda Y, Murayama N, Yamazaki H. 2023a. A comprehensive investigation of dog cytochrome P450 3A (CYP3A) reveals a functional role of newly identified CYP3A98 in small intestine. Drug Metab Dispos. 51(1):38–45. doi:10.1124/dmd.121.000749.
   PubMed Web of Science ®Google Scholar
• Uno Y, Morikuni S, Shiraishi M, Asano A, Murayama N, Yamazaki H. 2023b. Novel cytochrome P450 2C94 functionally metabolizes diclofenac and omeprazole in dogs. Drug Metab Dispos. 51(5):637–644. doi:10.1124/dmd.122.001236.
   PubMed Web of Science ®Google Scholar
• Uno Y, Noda Y, Morikuni S, Murayama N, Yamazaki H. 2023c. Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs. Xenobiotica. 53(3):140–148. doi:10.1080/00498254.2023.2211673.
   PubMed Web of Science ®Google Scholar
• Uno Y, Noda Y, Murayama N, Tsukiyama-Kohara K, Yamazaki H. 2023d. Novel cytochrome P450 1 (CYP1) genes in tree shrews are expressed and encode functional drug-metabolizing enzymes. Comp Biochem Physiol C Toxicol Pharmacol. 265:109534. doi:10.1016/j.cbpc.2022.109534.
   PubMed Web of Science ®Google Scholar
• Wong SG, Ramsden D, Dallas S, Fung C, Einolf HJ, Palamanda J, Chen L, Goosen TC, Siu YA, Zhang G, et al. 2021. Considerations from the innovation and quality induction working group in response to drug-drug interaction guidance from regulatory agencies: guidelines on model fitting and recommendations on time course for in vitro cytochrome P450 induction studies including impact on drug interaction risk assessment. Drug Metab Dispos. 49(1):94–110. doi:10.1124/dmd.120.000055.
   PubMed Web of Science ®Google Scholar
• Yajima K, Uno Y, Murayama N, Uehara S, Shimizu M, Nakamura C, Iwasaki K, Utoh M, Yamazaki H. 2014. Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. Drug Metab Dispos. 42(5):867–871. doi:10.1124/dmd.113.056804.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. 1997. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 283(2):434–442.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T. 2010. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol. 69(6):593–597. doi:10.1111/j.1365-2125.2010.03656.x.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, et al. 2002. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif. 24(3):329–337. doi:10.1006/prep.2001.1578.
   PubMed Web of Science ®Google Scholar
• Yamazaki H. 2017. Differences in toxicological and pharmacological responses mediated by polymorphic cytochromes P450 and related drug-metabolizing enzymes. Chem Res Toxicol. 30(1):53–60. doi:10.1021/acs.chemrestox.6b00286.
   PubMed Web of Science ®Google Scholar